Jaguar Health Declares Special Stock Dividend; Extends Debt Payments
Jaguar Health, Inc. announced a special stock dividend of Series R Convertible Preferred Stock to common stockholders and certain warrant holders of record on October 13, 2026. Each Series R share will convert into five common shares on November 2, 2026. The company stated the dividend is intended to reward shareholders and provide dilution protection as it evaluates strategic alternatives. Additionally, Jaguar Health amended royalty interest agreements with Uptown Capital and Streeterville Capital, extending the initiation of monthly payments to January 1, 2027, and extended the maturity date of a secured promissory note with Streeterville to the same date. The company also noted progress in its crofelemer development program for rare intestinal failure diseases.
Key Highlights
- Jaguar Health declared a special stock dividend of Series R Convertible Preferred Stock.
- The dividend is for holders of Common Stock and certain warrants as of October 13, 2026.
- Each Series R share will convert into five shares of Common Stock on November 2, 2026.
- The dividend aims to reward shareholders and protect against potential dilution.
- Napo Pharmaceuticals' crofelemer program for rare intestinal failure diseases is progressing, with an NDA filing for MVID expected mid-2027.
- Royalty interest payment initiations with Uptown Capital and Streeterville Capital extended to January 1, 2027.
- Maturity date of a $6.22M secured promissory note with Streeterville extended to January 1, 2027.
Price Impact
More from JAGX